A detailed history of Morgan Stanley transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Morgan Stanley holds 628,623 shares of PTGX stock, worth $24.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
628,623
Previous 345,293 82.05%
Holding current value
$24.7 Million
Previous $12 Million 136.13%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$33.72 - $47.33 $9.55 Million - $13.4 Million
283,330 Added 82.05%
628,623 $28.3 Million
Q2 2024

Oct 17, 2024

SELL
$24.66 - $34.8 $37.8 Million - $53.4 Million
-1,534,585 Reduced 81.63%
345,293 $12 Million
Q2 2024

Aug 14, 2024

SELL
$24.66 - $34.8 $37.8 Million - $53.4 Million
-1,534,585 Reduced 81.63%
345,293 $12 Million
Q1 2024

Oct 17, 2024

BUY
$21.79 - $32.15 $33.4 Million - $49.3 Million
1,534,585 Added 444.43%
1,879,878 $54.4 Million
Q1 2024

Aug 16, 2024

BUY
$21.79 - $32.15 $15 Million - $22.1 Million
688,041 Added 57.73%
1,879,878 $54.4 Million
Q1 2024

May 15, 2024

BUY
$21.79 - $32.15 $15 Million - $22.1 Million
688,041 Added 57.73%
1,879,878 $54.4 Million
Q4 2023

Aug 16, 2024

BUY
$14.05 - $23.44 $11.9 Million - $19.8 Million
846,544 Added 245.17%
1,191,837 $27.3 Million
Q4 2023

Feb 13, 2024

BUY
$14.05 - $23.44 $10.7 Million - $17.9 Million
762,833 Added 177.81%
1,191,837 $27.3 Million
Q3 2023

Nov 15, 2023

SELL
$16.68 - $23.66 $2.49 Million - $3.53 Million
-149,017 Reduced 25.78%
429,004 $7.16 Million
Q2 2023

Aug 14, 2023

SELL
$18.02 - $29.36 $17.9 Million - $29.1 Million
-992,489 Reduced 63.2%
578,021 $16 Million
Q1 2023

May 15, 2023

SELL
$10.78 - $25.38 $9.36 Million - $22 Million
-868,007 Reduced 35.6%
1,570,510 $36.1 Million
Q4 2022

Feb 14, 2023

BUY
$7.36 - $11.17 $1.55 Million - $2.36 Million
210,942 Added 9.47%
2,438,517 $26.6 Million
Q3 2022

Nov 14, 2022

BUY
$7.86 - $11.71 $3.55 Million - $5.28 Million
451,123 Added 25.39%
2,227,575 $18.8 Million
Q2 2022

Oct 27, 2022

BUY
$7.06 - $25.52 $3.1 Million - $11.2 Million
439,349 Added 32.86%
1,776,452 $14.1 Million
Q2 2022

Aug 15, 2022

BUY
$7.06 - $25.52 $3.1 Million - $11.2 Million
439,349 Added 32.86%
1,776,452 $14.1 Million
Q1 2022

Oct 27, 2022

SELL
$23.34 - $36.08 $10.3 Million - $15.9 Million
-439,349 Reduced 24.73%
1,337,103 $31.7 Million
Q1 2022

May 13, 2022

BUY
$23.34 - $36.08 $28.7 Million - $44.4 Million
1,229,687 Added 1144.79%
1,337,103 $31.7 Million
Q4 2021

Feb 14, 2022

SELL
$17.63 - $37.1 $6.47 Million - $13.6 Million
-366,899 Reduced 77.35%
107,416 $3.67 Million
Q3 2021

Nov 15, 2021

BUY
$12.95 - $49.69 $6.14 Million - $23.6 Million
474,315 New
474,315 $8.41 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.93B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.